0001558370-23-017657.txt : 20231106 0001558370-23-017657.hdr.sgml : 20231106 20231106072232 ACCESSION NUMBER: 0001558370-23-017657 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 231378109 BUSINESS ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 201-696-9345 MAIL ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 8-K 1 plx-20231106x8k.htm 8-K
0001006281false00010062812023-11-062023-11-06

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 6, 2023

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

    

001-33357

    

65-0643773

(State or other jurisdiction
of incorporation)

​

(Commission File Number)

​

(IRS Employer
Identification No.)

​

​

​

​

​

2 University Plaza

​

​

​

​

Suite 100

​

​

​

​

Hackensack, NJ

​

​

​

07601

(Address of principal executive offices)

​

​

​

(Zip Code)

​

 Registrant’s telephone number, including area code 201-696-9345

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.001 par value

PLX

NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

​

​

Item 2.02         Results of Operations and Financial Condition

On November 6, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01         Financial Statements and Exhibits

Exhibit No.

 

Description

99.1

​

Press Release dated November 6, 2023

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2023

PROTALIX BIOTHERAPEUTICS, INC.

​

​

 

 

 

 

 

By:

/s/ Dror Bashan

 

 

Name:

Dror Bashan

 

 

Title:

President and Chief Executive Officer

​

​

 EX-99.1 2 plx-20231106xex99d1.htm EX-99.1

​

​

Graphic

Exhibit 99.1

​

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EST

CARMIEL, Israel, November 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

“We continued our efforts this quarter towards turning Protalix into a fully-sustainable biopharmaceutical company with a growing pipeline of differentiated proprietary assets. With the approval of Elfabrio® by the U.S. FDA and the European Medicines Agency earlier this year, we are pleased to see our commercial partner Chiesi Global Rare Diseases hit the ground, both in the United States and the European Union. Additionally, Chiesi is continuing to position Elfabrio for future growth with additional approvals worldwide,” said Dror Bashan, Protalix’s President and Chief Executive Officer. “Our strong balance sheet coupled with our growing revenue stream allows us to focus on the continued development of our growing pipeline of assets, including PRX-115, our recombinant PEGylated uricase in development for the potential treatment of severe gout. We are continuing to enroll patients in our Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and immunogenicity of PRX-115, and look forward to continuing to progress this product candidate forward, Mr. Bashan continued. “We are proud of our achievements and look forward to an exciting future as a company with a proven platform and two approved drugs, a rich pipeline of product candidates in lucrative markets, a world-class team of dedicated employees, strong financial support with a solid balance sheet and an increasing stream of revenues.”

2023 Third Quarter and Recent Business Highlights

Regulatory Advancements

The Company, together with its development and commercialization partner, Chiesi Global Rare Diseases (Chiesi), a business unit of the Chiesi Group, continued to attain marketing authorizations around the world for Elfabrio (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease. Elfabrio, a PEGylated enzyme replacement therapy (ERT), is a recombinant human α-Galactosidase-A enzyme expressed in plant-cell culture that is designed to provide a long half-life.

·

On August 15, 2023, Chiesi announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Elfabrio in Great Britain for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.

·

On September 11, 2023, Swissmedic, the national authorization and supervisory authority for drugs and medical products in Switzerland, announced the approval of Elfabrio in Switzerland for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.

Clinical Developments

The Company continued to advance its First in Human (FIH) phase I clinical trial of PRX–115, a recombinant PEGylated uricase product candidate under development as a potential treatment for severe gout. To date, 32 patients have been dosed in the trial. The FIH trial is a double-blind, placebo-controlled, single ascending dose study designed to evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of PRX-115

in up to 56 patients with elevated uric acid levels (>6.0 mg/dL) and no previous exposure to PEGylated uricase. The study is being conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. We expect to announce top-line results from this study in mid-2024.

Corporate Developments

On September 14, 2023, Eliot Richard Forster, Ph.D. joined the Company’s Board of Directors as its Chairman, replacing former Chairman Zeev Bronfeld, who retired for personal reasons. In addition to his role as Chairman, Dr. Forster is serving as an independent director on the Company’s Nominating Committee.

Third Quarter 2023 Financial Highlights

·

The Company recorded revenues from selling goods of $10.2 million during the three months ended September 30, 2023, an increase of $1.4 million, or 16%, compared to revenues of $8.8 million for the three months ended September 30, 2022. The increase resulted primarily from an increase of $3.0 million in sales to Chiesi, following the approvals by the FDA and the EMA of Elfabrio, and of $0.6 million in sales to Brazil, partially offset by a $2.2 million decrease in sales to Pfizer.

·

The Company recorded revenues from license and R&D services of $0.2 million for the three months ended September 30, 2023, a decrease of $5.2 million, or 96%, compared to revenues of $5.4 million for the three months ended September 30, 2022. Revenues from license and R&D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. As of March 1, 2023, sponsorship of the extension studies was transferred to Chiesi, and Chiesi is now administering all open label extension studies.

·

Cost of goods sold was $4.9 million for the three months ended September 30, 2023, a decrease of $2.2 million, or 31%, from cost of goods sold of $7.1 million for the three months ended September 30, 2022. The decrease in cost of goods sold was primarily the result of the decrease in sales to Pfizer, partially offset by an increase in sales of Elfabrio to Chiesi and of Elelyso to Brazil.

·

For the three months ended September 30, 2023, the Company’s total research and development expenses were approximately $3.7 million comprised of approximately $1.0 million of subcontractor-related expenses, approximately $1.9 million of salary and related expenses, approximately $0.2 million of materials-related expenses and approximately $0.6 million of other expenses. For the three months ended September 30, 2022, our total research and development expenses were approximately $7.4 million comprised of approximately $4.9 million in subcontractor-related expenses, approximately $1.7 million of salary and related expenses, approximately $0.2 million of materials-related expenses and approximately $0.6 million of other expenses. Total decrease in research and developments expenses was $3.7 million, or 50%, compared to the three months ended September 30, 2022. The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and the regulatory processes related to the Biologics License Application (BLA) and Marketing Authorization Application (MAA) review of Elfabrio by the applicable regulatory agencies.

·

Selling, general and administrative expenses were $3.7 million for the three months ended September 30, 2023, an increase of $0.9 million, or 32%, compared to $2.8 million for the three months ended September 30, 2022. The increase resulted primarily from an increase of approximately $0.6 million in salary and related expenses due to one-time cash bonuses and an increase in share-based compensation.

·

Financial income, net was $0.2 million for the three months ended September 30, 2023, compared to financial expenses, net of $0.4 million for the three months ended September 30, 2022. The change resulted primarily from an increase of $0.3 million in interest income.

·

In the three months ended September 30, 2023, the Company recorded income taxes of approximately $0.1 million which were primarily the result of the provision for current taxes in respect of Section 174 of the U.S. Tax Cuts and Jobs Act, which was enacted in December 2017.

·

Cash, cash equivalents and short term bank deposits were approximately $41.0 million at September 30, 2023.

·

Net loss for the three months ended September 30, 2023 was approximately $1.9 million, or $0.03 per share, basic, and $0.04 per share, diluted, compared to a net loss of $3.6 million, or $0.07 per share, basic and diluted, for the same period in 2022.

Conference Call and Webcast Information
The Company will host a conference call today, November 6, 2023, at 8:30 a.m. EST, to review the regulatory, clinical and corporate developments, which will also be available by webcast. To participate in the conference call, please dial the following numbers prior to the start of the call:

Conference Call Details:

Date:

Monday, November 6, 2023

Time:

8:30 a.m. Eastern Standard Time (EST)

Toll Free:

1-877-423-9813

Israeli Toll Free:

1-809-406 247

International:

1-201-689-8573

Conference ID:

13741587

Call me™:

https://tinyurl.com/2tsadwma

​

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details:

The conference will be webcast live from the Company’s website and will be available via the following links:

Company Link:

https://protalixbiotherapeutics.gcs-web.com/events0

Webcast Link:

https://tinyurl.com/362f74wx

Conference ID:

13741587

​

Participants are requested to access the websites at least 15 minutes ahead of the conference call to register, download and install any necessary audio software.

A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company’s website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the

worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix’s first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix’s second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates:

PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms “expect,” “anticipate,” “believe,” “estimate,” “project,” “may,” “plan,” “will,” “would,” “should” and “intend,” and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the commercialization of Elfabrio, our approved product for the treatment of adult patients with Fabry disease; risks relating to Elfabrio’s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product; risks related to our commercialization partner’s ability to obtain and maintain reimbursement for Elfabrio, and the extent to which patient assistance programs and co-pay programs are utilized; the possible disruption of our operations due to the war declared by Israel’s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers; the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen for Elfabrio; risks related to the regulatory approval and commercial success of our other product and product candidates, if approved; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials; risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; risks relating to our evaluation and pursuit of strategic partnerships; the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks relating to our ability to manage our relationship with our collaborators,

distributors or partners, including, but not limited to, Pfizer and Chiesi; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish; risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement; risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies; risks related to our supply of drug products to Pfizer; potential product liability risks, and risks of securing adequate levels of related insurance coverage; the possibility of infringing a third-party’s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.

Investor Contact

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390

chuck@lifesciadvisors.com

###

​

PROTALIX BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

(Unaudited)

​

​

​

​

​

​

​

​

​

​

    

September 30, 2023

    

December 31, 2022

 

​

​

​

​

​

​

​

​

ASSETS

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

CURRENT ASSETS:

​

​

​

​

​

​

​

Cash and cash equivalents

​

$

20,408

​

$

17,111

​

Short-term bank deposits

​

​

20,567

​

​

5,069

​

Accounts receivable – Trade

​

​

8,935

​

​

4,586

​

Other assets

​

​

1,125

​

​

1,310

​

Inventories

​

​

21,583

​

​

16,804

​

Total current assets

​

$

72,618

​

$

44,880

​

​

​

​

​

​

​

​

​

NON-CURRENT ASSETS:

​

​

​

​

​

​

​

Funds in respect of employee rights upon retirement

​

$

1,260

​

$

1,267

​

Property and equipment, net

​

​

4,684

​

​

4,553

​

Deferred income tax asset

​

​

3,092

​

​

—

​

Operating lease right of use assets

​

​

5,915

​

​

5,087

​

Total assets

​

$

87,569

​

$

55,787

​

​

​

​

​

​

​

​

​

LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

CURRENT LIABILITIES:

​

​

​

​

​

​

​

Accounts payable and accruals:

​

​

​

​

​

​

​

Trade

​

$

3,114

​

$

5,862

​

Other

​

​

18,740

​

​

12,271

​

Operating lease liabilities

​

​

1,313

​

​

1,118

​

Contracts liability

​

​

—

​

​

13,178

​

Convertible notes

​

​

20,192

​

​

—

​

Total current liabilities

​

$

43,359

​

$

32,429

​

​

​

​

​

​

​

​

​

LONG TERM LIABILITIES:

​

​

​

​

​

​

​

Convertible notes

​

​

​

​

$

28,187

​

Liability for employee rights upon retirement

​

$

1,461

​

​

1,642

​

Operating lease liabilities

​

​

4,502

​

​

4,169

​

Total long term liabilities

​

$

5,963

​

$

33,998

​

Total liabilities

​

$

49,322

​

$

66,427

​

​

​

​

​

​

​

​

​

COMMITMENTS

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

STOCKHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

​

​

38,247

​

​

(10,640)

​

Total liabilities and stockholders’ equity (net of capital deficiency)

​

$

87,569

​

$

55,787

​

​

​

PROTALIX BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share and per share data)

(Unaudited)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Nine Months Ended

    

Three Months Ended

 

​

​

September 30, 2023

​

September 30, 2022

​

September 30, 2023

​

September 30, 2022

​

REVENUES FROM SELLING GOODS

​

$

30,309

​

$

21,222

​

$

10,168

​

$

8,812

​

REVENUES FROM LICENSE AND R&D SERVICES

​

​

24,699

​

​

17,799

​

​

177

​

​

5,371

​

TOTAL REVENUE

​

​

55,008

​

​

39,021

​

​

10,345

​

​

14,183

​

COST OF GOODS SOLD (1)

​

​

(14,126)

​

​

(17,195)

​

​

(4,893)

​

​

(7,074)

​

RESEARCH AND DEVELOPMENT EXPENSES (2)

​

​

(13,991)

​

​

(23,732)

​

​

(3,669)

​

​

(7,386)

​

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)

​

​

(10,816)

​

​

(8,613)

​

​

(3,670)

​

​

(2,848)

​

OPERATING INCOME (LOSS)

​

​

16,075

​

​

(10,519)

​

​

(1,887)

​

​

(3,125)

​

FINANCIAL EXPENSES

​

​

(2,406)

​

​

(1,879)

​

​

(460)

​

​

(639)

​

FINANCIAL INCOME

​

​

1,323

​

​

1,211

​

​

628

​

​

197

​

FINANCIAL INCOME (EXPENSES), NET

​

​

(1,083)

​

​

(668)

​

​

168

​

​

(442)

​

INCOME (LOSS) BEFORE TAXES ON INCOME

​

​

14,992

​

​

(11,187)

​

​

(1,719)

​

​

(3,567)

​

TAXES ON INCOME

​

​

(636)

​

​

—

​

​

(133)

​

​

—

​

NET INCOME (LOSS) FOR THE PERIOD

​

$

14,356

​

$

(11,187)

​

$

(1,852)

​

$

(3,567)

​

EARNINGS (LOSS) PER SHARE OF COMMON STOCK:

​

​

​

​

​

​

​

​

​

​

​

​

​

BASIC

​

$

0.22

​

$

(0.24)

​

$

(0.03)

​

$

(0.07)

​

DILUTED

​

$

0.16

​

$

(0.24)

​

$

(0.04)

​

$

(0.07)

​

WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK

​

​

​

​

​

​

​

​

​

​

​

​

​

USED IN COMPUTING EARNINGS (LOSS) PER SHARE:

​

​

​

​

​

​

​

​

​

​

​

​

​

BASIC

​

​

65,811,506

​

​

47,582,733

​

​

72,281,681

​

​

49,498,105

​

DILUTED

​

​

81,040,281

​

​

47,582,733

​

​

83,782,679

​

​

49,498,105

​

(1) Includes share-based compensation

​

$

299

​

$

58

​

$

195

​

$

36

​

(2) Includes share-based compensation

​

$

506

​

$

275

​

$

182

​

$

114

​

(3) Includes share-based compensation

​

$

1,276

​

$

1,213

​

$

720

​

$

272

​

​

 GRAPHIC 3 plx-20231106xex99d1001.jpg GRAPHIC begin 644 plx-20231106xex99d1001.jpg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end EX-101.SCH 4 plx-20231106.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 plx-20231106_lab.xml EX-101.LAB EX-101.PRE 6 plx-20231106_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 06, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 06, 2023
Securities Act File Number 001-33357
Entity Registrant Name Protalix BioTherapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 65-0643773
Entity Address, Address Line One 2 University Plaza
Entity Address, Address Line Two Suite 100
Entity Address, State or Province NJ
Entity Address, City or Town Hackensack
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 696-9345
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol PLX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Entity Central Index Key 0001006281
Amendment Flag false
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.23.3
N-2
Nov. 06, 2023
Cover [Abstract]  
Entity Central Index Key 0001006281
Amendment Flag false
Securities Act File Number 001-33357
Document Type 8-K
Entity Registrant Name Protalix BioTherapeutics, Inc.
Entity Address, Address Line One 2 University Plaza
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Hackensack
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 696-9345
Entity Emerging Growth Company false
XML 9 plx-20231106x8k_htm.xml IDEA: XBRL DOCUMENT 0001006281 2023-11-06 2023-11-06 0001006281 false 8-K 2023-11-06 Protalix BioTherapeutics, Inc. DE 001-33357 65-0643773 2 University Plaza Suite 100 Hackensack NJ 07601 201 696-9345 false false false false Common stock, $0.001 par value PLX NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://protalix.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports plx-20231106.xsd plx-20231106_lab.xml plx-20231106_pre.xml plx-20231106x8k.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "plx-20231106x8k.htm": { "nsprefix": "plx", "nsuri": "http://protalix.com/20231106", "dts": { "schema": { "local": [ "plx-20231106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/cef/2022/cef-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd" ] }, "labelLink": { "local": [ "plx-20231106_lab.xml" ] }, "presentationLink": { "local": [ "plx-20231106_pre.xml" ] }, "inline": { "local": [ "plx-20231106x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 200, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_11_6_2023_To_11_6_2023_OO2-FJMNhEaSbzp2_qzAGA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "plx-20231106x8k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_6_2023_To_11_6_2023_OO2-FJMNhEaSbzp2_qzAGA", "name": "dei:DocumentPeriodEndDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "plx-20231106x8k.htm", "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/cef/role/N2", "longName": "995470 - Disclosure - N-2", "shortName": "N-2", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "2", "firstAnchor": { "contextRef": "Duration_11_6_2023_To_11_6_2023_OO2-FJMNhEaSbzp2_qzAGA", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "plx-20231106x8k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to3": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ExpenseExampleYears1to3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "auth_ref": [] }, "cef_OtherAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherAnnualExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "cef_NetExpenseOverAssetsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "NetExpenseOverAssetsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "auth_ref": [] }, "cef_WaiversAndReimbursementsOfFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "WaiversAndReimbursementsOfFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "cef_AnnualDividendPaymentInitial": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualDividendPaymentInitial", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "auth_ref": [] }, "cef_ExpenseExampleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ExpenseExampleTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "auth_ref": [] }, "cef_TotalAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "TotalAnnualExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AcquiredFundFeesAndExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "auth_ref": [] }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cef_ExpenseExampleYear01": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ExpenseExampleYear01", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "cef_OtherSecurityDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherSecurityDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "auth_ref": [] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r10", "r11", "r12", "r13" ] }, "cef_ExpenseExampleYears1to5": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ExpenseExampleYears1to5", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "WarrantsOrRightsExercisePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to10": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ExpenseExampleYears1to10", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "auth_ref": [] }, "cef_PurposeOfFeeTableNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "PurposeOfFeeTableNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledPeriodDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "WarrantsOrRightsCalledPeriodDate", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "cef_BasisOfTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "BasisOfTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionFeesBasisNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionFeesBasisMaximum", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionFeesBasisMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "auth_ref": [] }, "cef_OtherExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r0" ] }, "cef_SeniorSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationMinimumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "IncentiveAllocationMinimumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesCoveragePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesCoveragePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "IncentiveAllocationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r6" ] }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "IncentiveAllocationMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "auth_ref": [] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "cef_FinancialHighlightsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "FinancialHighlightsAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r22" ] }, "cef_SeniorSecuritiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "cef_RiskTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "RiskTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit" } } }, "auth_ref": [] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r21" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r26" ] }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r0" ] }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "auth_ref": [] }, "cef_GeneralDescriptionOfRegistrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "GeneralDescriptionOfRegistrantAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "auth_ref": [] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r15" ] }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "InvestmentObjectivesAndPracticesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "auth_ref": [] }, "cef_RiskFactorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "RiskFactorsTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r0" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "cef_AllRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AllRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "auth_ref": [] }, "cef_RiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "RiskAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r0" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r16" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "cef_AnnualDividendPayment": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualDividendPayment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "auth_ref": [] }, "cef_EffectsOfLeverageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "EffectsOfLeverageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r22" ] }, "cef_LongTermDebtPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtPrincipal", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "auth_ref": [] }, "cef_LongTermDebtTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "auth_ref": [] }, "cef_LowestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LowestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "auth_ref": [] }, "cef_LatestSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LatestSharePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Share Price" } } }, "auth_ref": [] }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "PreferredStockRestrictionsArrearageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "HighestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "auth_ref": [] }, "cef_PreferredStockRestrictionsOtherTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "PreferredStockRestrictionsOtherTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "auth_ref": [] }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "auth_ref": [] }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "RightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [] }, "cef_LongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://protalix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "cef_SecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "auth_ref": [] }, "cef_LatestNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LatestNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest NAV" } } }, "auth_ref": [] }, "cef_LongTermDebtStructuringTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtStructuringTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "auth_ref": [] }, "cef_SharePricesNotActualTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SharePricesNotActualTransactionsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "auth_ref": [] }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "cef_NoPublicTradingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "NoPublicTradingTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "auth_ref": [] }, "cef_OutstandingSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OutstandingSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "auth_ref": [] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r15" ] }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "auth_ref": [] }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "WarrantsOrRightsCalledAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "auth_ref": [] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r21" ] }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "auth_ref": [] }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r20" ] }, "cef_ProspectusTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ProspectusTable", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "auth_ref": [] }, "cef_NoTradingHistoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "NoTradingHistoryTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityAuthorizedShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OutstandingSecurityAuthorizedShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "auth_ref": [] }, "cef_LatestPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LatestPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OutstandingSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "auth_ref": [] }, "cef_DistributionsMayReducePrincipalTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "DistributionsMayReducePrincipalTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityNotHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OutstandingSecurityNotHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OutstandingSecurityHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "auth_ref": [] }, "cef_SecurityDividendsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityDividendsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "auth_ref": [] }, "cef_CapitalStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "CapitalStockTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r10", "r11", "r12", "r13" ] }, "cef_ProspectusLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ProspectusLineItems", "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "auth_ref": [] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r20" ] }, "cef_SecurityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security [Axis]" } } }, "auth_ref": [] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r24" ] }, "cef_SecurityVotingRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityVotingRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "auth_ref": [] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r24" ] }, "cef_AllSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AllSecuritiesMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "All Securities:" } } }, "auth_ref": [] }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "auth_ref": [] }, "cef_SecurityLiquidationRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityLiquidationRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "auth_ref": [] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r24" ] }, "cef_SecurityObligationsOfOwnershipTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityObligationsOfOwnershipTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "auth_ref": [] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r15" ] }, "cef_SecurityLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SecurityLiabilitiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "auth_ref": [] }, "cef_ReturnAtPlusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ReturnAtPlusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "auth_ref": [] }, "cef_InterestExpensesOnBorrowingsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "InterestExpensesOnBorrowingsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "auth_ref": [] }, "cef_OtherMasterFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherMasterFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "auth_ref": [] }, "cef_EffectsOfLeveragePurposeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "EffectsOfLeveragePurposeTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r23" ] }, "cef_OtherTransactionExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "auth_ref": [] }, "cef_OtherSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "HighestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "auth_ref": [] }, "cef_AnnualExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "auth_ref": [] }, "cef_SharePriceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SharePriceTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r7", "r8" ] }, "cef_PrimaryShelfFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "PrimaryShelfFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "auth_ref": [] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r25" ] }, "cef_ManagementFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ManagementFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "auth_ref": [] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r25" ] }, "cef_RegisteredClosedEndFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "RegisteredClosedEndFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "auth_ref": [] }, "cef_AnnualInterestRateInitialPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualInterestRateInitialPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "auth_ref": [] }, "cef_PrimaryShelfQualifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "PrimaryShelfQualifiedFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "auth_ref": [] }, "cef_AnnualDividendPaymentCurrent": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualDividendPaymentCurrent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "auth_ref": [] }, "cef_BusinessDevelopmentCompanyFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "BusinessDevelopmentCompanyFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "auth_ref": [] }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "DividendAndInterestExpensesOnShortSalesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "auth_ref": [] }, "cef_DividendReinvestmentAndCashPurchaseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "DividendReinvestmentAndCashPurchaseFees", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "auth_ref": [] }, "cef_AnnualInterestRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualInterestRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "auth_ref": [] }, "cef_IncentiveFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "IncentiveFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r9", "r10", "r14" ] }, "cef_DistributionServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "DistributionServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "auth_ref": [] }, "cef_IntervalFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "IntervalFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherAnnualExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r9", "r10", "r14" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r25" ] }, "cef_OtherAnnualExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherAnnualExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "auth_ref": [] }, "cef_ReturnAtMinusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ReturnAtMinusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "auth_ref": [] }, "cef_EffectsOfLeverageTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "EffectsOfLeverageTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "auth_ref": [] }, "cef_LoanServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LoanServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "auth_ref": [] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r27" ] }, "cef_NewCefOrBdcRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "NewCefOrBdcRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "WarrantsOrRightsCalledTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "auth_ref": [] }, "cef_AnnualCoverageReturnRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualCoverageReturnRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "auth_ref": [] }, "cef_AnnualInterestRateCurrentPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "AnnualInterestRateCurrentPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "auth_ref": [] }, "cef_ReturnAtMinusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ReturnAtMinusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "auth_ref": [] }, "cef_BdcFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "BdcFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "auth_ref": [] }, "cef_OtherFeederFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherFeederFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "auth_ref": [] }, "cef_FeeTableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "FeeTableAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "auth_ref": [] }, "cef_OtherSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "auth_ref": [] }, "cef_DividendExpenseOnPreferredSharesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "DividendExpenseOnPreferredSharesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "auth_ref": [] }, "cef_ShareholderTransactionExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ShareholderTransactionExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "auth_ref": [] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r18" ] }, "cef_OtherAnnualExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherAnnualExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherAnnualExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "auth_ref": [] }, "cef_ReturnAtZeroPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ReturnAtZeroPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "cef_OtherTransactionExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "OtherTransactionExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "auth_ref": [] }, "cef_SalesLoadPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "SalesLoadPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "auth_ref": [] }, "cef_ReturnAtPlusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "ReturnAtPlusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "auth_ref": [] }, "plx_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://protalix.com/20231106", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "auth_ref": [] }, "cef_LowestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "LowestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "cef_UnderwritersCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2022", "localname": "UnderwritersCompensationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r22": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r23": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r24": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r25": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r26": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r27": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" } } } ZIP 16 0001558370-23-017657-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-017657-xbrl.zip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end